Collin Harry, Huang Benjamin, Siriwardana Amila, Harris Craig, Stevenson Andrew, Navaratnam Anojan, Esler Rachel, Roberts Matthew J
Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
Department of Urology, Royal Brisbane & Women's Hospital, Brisbane, QLD, Australia.
J Robot Surg. 2025 May 23;19(1):229. doi: 10.1007/s11701-025-02395-1.
Prostate cancer (PC) and rectal cancer (RC) are common and can require complex management, especially when presenting synchronously or with invasive characteristics. Robotic surgery has emerged as a viable option for managing these challenging cases; however, the outcomes are yet to be summarised or compared to traditional approaches. This systematic review aims to evaluate the feasibility, oncological outcomes, and functional results of simultaneous robotic-assisted resections of the prostate and rectum. Following prior protocol registration (PROSPERO: CRD42023449872) and according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines, we conducted a systematic search across multiple databases, selecting studies that involved simultaneous bladder-sparing robotic-assisted prostatectomy and rectal resection. The Joanna Briggs Institute tool was used for risk of bias assessment. Data on patient demographics, treatment details, post-operative course, and functional and oncological outcomes were extracted and analysed. From 1357 identified records, 25 studies met our inclusion criteria resulting in 45 cases/patients. The median patient age was 62 years. Diverse treatment backgrounds and outcome definitions were recorded. Median operative time was 548 min and median estimated blood loss was 450 mL. The overall complication rate was 44.4%, with major complications (Clavien-Dindo III) occurring in 17.8% of cases. Surgical margins were negative in 92.6% of cases. Continence recovery occurred for most (78.6%) of the cases reporting on urinary function. Simultaneous robotic-assisted prostatectomy and rectal resection appears to be a feasible, safe and oncologically effective approach with satisfactory oncological and functional outcomes for managing patients with synchronous or invasive PC and RC.
前列腺癌(PC)和直肠癌(RC)很常见,可能需要复杂的治疗,尤其是当它们同时出现或具有浸润性特征时。机器人手术已成为处理这些具有挑战性病例的一种可行选择;然而,其结果尚未得到总结或与传统方法进行比较。本系统评价旨在评估同时进行机器人辅助前列腺和直肠切除术的可行性、肿瘤学结果及功能结果。在预先进行方案注册(PROSPERO:CRD42023449872)后,根据系统评价和Meta分析的首选报告项目(PRISMA)指南,我们在多个数据库中进行了系统检索,选择了涉及同时保留膀胱的机器人辅助前列腺切除术和直肠切除术的研究。采用乔安娜·布里格斯研究所工具进行偏倚风险评估。提取并分析了患者人口统计学、治疗细节、术后病程以及功能和肿瘤学结果的数据。从1357条识别记录中,25项研究符合我们的纳入标准,共45例患者。患者中位年龄为62岁。记录了不同的治疗背景和结果定义。中位手术时间为548分钟,中位估计失血量为450毫升。总体并发症发生率为44.4%,严重并发症(Clavien-Dindo III级)发生率为17.8%。92.6%的病例手术切缘阴性。大多数报告了尿功能的病例(78.6%)实现了控尿恢复。同时进行机器人辅助前列腺切除术和直肠切除术似乎是一种可行、安全且在肿瘤学上有效的方法,对于治疗同时患有PC和RC的同步或浸润性患者具有令人满意的肿瘤学和功能结果。